CRISPR Therapeutics AG (CRSP) stock closed with a 1.38% increase, underperformed S&P 500.

From Nasdaq: 2025-05-02 17:50:00

CRISPR Therapeutics AG (CRSP) closed at $38.25, a +1.38% increase from the previous day, trailing behind S&P 500, Dow, and Nasdaq gains. In the past month, CRSP shares rose by 15.52%, while the Medical sector and S&P 500 saw losses.

Anticipation surrounds CRISPR Therapeutics AG’s upcoming financial results, with an expected EPS of -$1.27, a 11.19% rise from the previous year. Revenue is projected to reach $5.24 million, a 947.2% increase year-over-year. Analysts are closely monitoring estimate revisions, which can impact stock prices.

The Zacks Rank system, with CRISPR Therapeutics AG currently ranked at #3 (Hold), has a track record of outperforming. The Medical – Biomedical and Genetics industry ranks in the top 35% of industries. Stay updated on stock metrics through Zacks.com for future trading sessions.

Zacks experts have identified 5 stocks set to potentially double by 2024, with past picks soaring +143.0%, +175.9%, +498.3%, and +673.0%. These under-the-radar stocks present an opportunity for significant growth. Visit Zacks.com for the latest recommendations and stock analysis reports.



Read more at Nasdaq: CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts